Glens Falls Hospital

100 Park Street, Glens Falls, NY 12801 518.926.1000

Clinical Trials

Key:

C = CALGB
E = ECOG
N = NSABP
P = Pharmacy
R = RTOG
S = SWOG
CTSU= NCI Cancer Trials Support Unit
V = Vermont Cancer Center

 

Updated 6-16-15

 

Breast:


CTSU NRG-BR003

  • Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

N B51  

  • A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (Pre-Activation Only) - On Hold

PUMA NER 1301          

  • (NALA) A Study of Neratinib Plus Capecitabine vs. Lapatinib Plus Capecitabine in Patients with Her2+ Metastatic Breast Ca who Have Received >/= 2 Prior Her2-Directed Regimens in the Metastatic Setting

P MONALEESA-3 (LEE011F2301)

  • A randomized double-blind, placebo- controlled study of ribociclib in combination with fulvestrant for the treatment of postmenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer who have received no or only one line of prior endocrine treatment

 

Carcinoid:

CTSU A021202  

  • Prospective randomized phase II trial of Pazopanib vs. placebo in patients with progressive carcinoid tumors

Head and Neck:

CTSU RTOG 0920

  • A Phase III Study of Postoperative Radiation Therapy (IMRT) =/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer

 

Lung: SCLC Limited:
C 30610

  • Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide

NSCLC Limited

CTSU A151216 NSCLC-

  • -Genetic Testing For Patients with Resectable or Resected Lung Cancer (ALCHEMIST)

CTSU E4512

  • A Phase III Double-Blind Trial for Surgically Resected Early Stage NSCLC: Crizotinib vs. Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein. (ALCHEMIST)

CTSU A081105 Alchemist-

  • A Phase III Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant NSCLC (ALCHEMIST)

 

NSCLC Advanced

  • P Merck KEYNOTE-189 A Randomized, Double-Blind, Phase III Study of Platinum+ Pemetrexed Chemotherapy with or without Pembrolizumab (MK-3475) in First Line Metastatic Non-squamous NSCLC Subjects (Hold-Pending SIV

 

 

Lymphoma:

CTSU E1411  

  • Phase II 4-Arm Study In Patients 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV LR)

P Celgene Magnify CC-5013-NHL-008

  • Randomized Study of Lenalidomide (CC-5013) plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-agent Maintenance vs Rituximab Maintenance in Subjects with Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma (Hold-Pending SIV)

 

Pancreatic:

CTSU RTOG-0848

  •  A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma

Prostate:

CTSU S1216  

  • A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide inPatients With Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer

 

Renal:

CTSU S0931  

  • EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, a Phase III Study

 

PREVENTION:

CTSU S0820

  • A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers s/p one year after primary resection in Patients with Stage 0-III Colon Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)

 

REGISTRIES:

P Registry

  • Breast Cancer Collaborative Registry (BCCR) for patients who have breast cancer that has been recently diagnosed, have a history of breast cancer, or are at high risk of developing breast cancer, or because relatives have been diagnosed with breast cancer.

P Registry

  • informCLLâ„¢: A Disease Registry for Patients with Chronic Lymphocytic Leukemia

P Registry

  • Celgene Corporation Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

 

Treatment Protocols

Glens Falls Hospital
Pruyn Pavilion
Research Office
Phone: (518) 926-6701
Fax: (518) 926-1954

Staff Directory

Investigators:

Robert W. Sponzo, M.D.
Aqeel Gillani, M.D.
John Stoutenburg, M.D.
Eric Pillemer, M.D.
Darci Gaiotti-Grubbs, M.D.
Mark Hoffman, M.D.

Alex Frank, M.D.

 

Clinical Research Support:

Beth Ann Brundage, RN, OCN
Nannette Oberhelman, CCRP
Jean VanAuken, RPA-C